Fish oil prevents excessive accumulation of subcutaneous fat caused by an adverse effect of pioglitazone treatment and positively changes adipocytes in KK mice by 飯塚, 譲 et al.
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Pioglitazone,  a thiazolidinedione  (TZD),  is  widely  used  as an  insulin  sensitizer  in  the  treatment  of  type
2 diabetes.  However,  body  weight  gain  is  frequently  observed  in  TZD-treated  patients.  Fish  oil  improves
lipid  metabolism  dysfunction  and obesity.  In this  study,  we  demonstrated  suppression  of  body  weight
gain  in  response  to pioglitazone  administration  by  combination  therapy  of pioglitazone  and  ﬁsh  oil  in type
2 diabetic  KK mice.  Male  KK  mice  were  fed  experimental  diets  for  8  weeks.  In  safﬂower  oil (SO),  safﬂower
oil/low-dose  pioglitazone  (S/PL),  and  safﬂower  oil/high-dose  pioglitazone  (S/PH)  diets,  20%  of  calories
were  provided  by safﬂower  oil  containing  0%, 0.006%,  or 0.012%  (wt/wt)  pioglitazone,  respectively.  In
ﬁsh  oil  (FO),  ﬁsh oil/low-dose  pioglitazone  (F/PL),  and ﬁsh  oil/high-dose  pioglitazone  (F/PH)  diets,  20%  of
calories  were  provided  by a  mixture  of ﬁsh  oil  and  safﬂower  oil.  Increased  body  weight  and  subcutaneous
fat  mass  were  observed  in the S/PL  and  S/PH  groups;  however,  diets  containing  ﬁsh  oil were  found  to
ameliorate  these  changes.  Hepatic  mRNA  levels  of lipogenic  enzymes  were  signiﬁcantly  decreased  in  ﬁsh
oil-fed  groups.  These  ﬁndings  demonstrate  that  the  combination  of  pioglitazone  and  ﬁsh  oil decreases
subcutaneous  fat accumulation,  ameliorating  pioglitazone-induced  body  weight  gain,  through  ﬁsh  oil-
mediated  inhibition  of  hepatic  de  novo  lipogenesis.
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1. Introduction
Lifestyle-related diseases, particularly type 2 diabetes, are
increasingly becoming a major global health issue associated with
excessive caloric intake and decreasing physical activity [1]. Type
2 diabetes epidemic has grown rapidly worldwide and is known
to affect an estimated 387 million people (Diabetes Atlas 2014
update, International Diabetes Federation, IDF, 2014). The major
pathogenic mechanism underlying type 2 diabetes is thought
to be insulin resistance (IR) associated with abdominal obesity
[2]. Excessive amounts of unconsumed calories result in triglyc-
eride accumulation in adipocytes, particularly in visceral fat tissue,
leading to cellular hypertrophy and stimulation of inﬂammatory
cytokine production [3–5]. In addition, large amounts of free fatty
acids (FFAs) derived from hypertrophic adipocytes are transferred
to insulin responsive organs, such as the liver, skeletal muscle, and
pancreas, as “ectopic fat” leading to decreased insulin sensitiv-
ity [6,7]. Adiponectin, an adipose tissue-derived secreted protein
with insulin-sensitizing activity, has been shown to be decrease
in abdominal obesity, with a negative correlation found between
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Table  1
Composition of experimental diets.
Group Ingredients (g)
SO S/PL S/PH FO F/PL F/PH
Safﬂower oil 8 8 8 4 4 4
Fish  oil 4 4 4
Casein 20 20 20 20 20 20
Sucrose 10.37 10.37 10.37 10.37 10.37 10.37
-starch 51.83 51.83 51.83 51.83 51.83 51.83
Vitamin mixa 1 1 1 1 1 1
Mineral mixa 3.5 3.5 3.5 3.5 3.5 3.5
Cellulose powder 5 5 5 5 5 5
l-Cystin 0.3 0.3 0.3 0.3 0.3 0.3
t-Butylhydroquinone 0.0016 0.0016 0.0016 0.0016 0.0016 0.0016
Pioglitazone 0.006 0.012 0.006 0.012
Total 100.00 100.01 100.01 100.00 100.01 100.01
Energy (kcal/100 g) 374.02 374.00 373.99 374.02 374.00 373.99
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a Vitamin and mineral mix  were based on the AIN-93 M formation. Vitamin mix
ubstituted 0.25% sucrose for choline bitartrate.
lasma adiponectin levels and body mass index [8]. Through the
nteractions of these complex mechanisms, obesity-induced accu-
ulation of visceral fat is thought to contribute to IR through
lipotoxicity” [2].
Thiazolidinediones (TZDs), potent and selective ligands for
eroxisome proliferator-activated receptor gamma  (PPAR), are
idely used clinically in the treatment of type 2 diabetes as
nsulin-sensitizing agents [9]. TZDs promote the differentiation
f preadipocytes into mature adipocytes and apoptosis of hyper-
rophic adipocyte, a process termed “adipose tissue remodeling.”
urther, TZDs increase plasma adiponectin levels and reduce the
roduction of adipocytokines, such as tumor necrosis factor-
 (TNF-) and monocyte chemoattractant protein-1 (MCP-1),
hereby ameliorating adipocytokine-mediated IR [10–13]. Thus,
he antihyperglycemic effects of TZDs are thought to be medi-
ted independently of increased insulin production, suggesting the
reatest utility of TZDs lies in the treatment of type 2 diabetic
atients without pancreatic beta cell failure [14,15]. Many stud-
es have demonstrated TZDs have multifaceted utility including the
mprovement of lipid proﬁles [16,17], amelioration of nonalcoholic
teatohepatitis [18,19], systemic anti-inﬂammatory effects [20],
nd the prevention of arteriosclerosis [21,22]. And, TZD-induced
adipose tissue remodeling” is thought to lead increased absorp-
ion and storage of excess lipids by small adipocytes newly derived
n response to the effects of TZDs [13,23]. However, body weight
ain is considered a major adverse effect of TZD therapy following
esults from animal studies and several clinical trials in patients
ith type 2 diabetes [24,25]. Moreover, subcutaneous fat accumu-
ation is frequently observed in patients administered TZDs [26].
Fish oil contains eicosapentaenoic acid (EPA, 20-5) and docosa-
exaenoic acid (DHA, 22-6), which have been shown to have
eneﬁcial effects in hyperlipidemia, fatty liver, atherosclerosis, and
ardiovascular disease in both animal models and clinical trials
27–30]. Hepatic de novo lipogenesis is mainly controlled by sterol
egulatory element-binding proteins (SREBPs), transcription fac-
ors that regulate the expression of genes involved in lipogenesis.
REBP-1c, one of the SREBPs isoforms, plays a particularly criti-
al role in fatty acid synthesis through the regulation of several
arget genes including fatty acid synthase (FAS), acetyl-CoA car-
oxylase (ACC), and stearoyl-CoA desaturase 1 (SCD-1) [31]. Fish
il consumption has been shown to decrease mRNA expression and
ature protein levels of SREBP-1c [32,33]. Additionally, fatty acid
xidation has been shown to be stimulated by ﬁsh oil consumption
hrough stimulation of peroxisome proliferator-activated recep-
or alpha (PPAR), a nuclear receptor involved in the regulation of
umerous target genes, such as acyl-CoA oxidase (AOX) and uncou-eports 3 (2016) 4–14 5
pling protein 2 (UCP-2) [32,34]. In our previous study of female KK
mice, we  demonstrated a diet with 25% of total calories from ﬁsh
oil had numerous beneﬁcial effects including suppression of body
weight gain associated with whole-body adiposity, improvements
in lipid metabolism dysfunction, the prevention of hyperinsuline-
mia  due to increased fatty acid oxidation, and decreased lipid
synthesis [35]. Therefore, we hypothesized that the combina-
tion of pioglitazone and ﬁsh oil prevents pioglitazone-induced
body weight gain attributed to the accumulation of subcutaneous
fat and exerts synergistic beneﬁcial effects on glucose and lipid
metabolism. In this study, we  evaluated the combined effects of
pioglitazone and ﬁsh oil in mice of type 2 diabetes to test the above
hypothesis and inform the development of novel TZD treatment
approaches.
2. Materials and methods
2.1. Animals and diets
All animal studies were approved by the Guidelines of Insti-
tutional Animal Care and Use Committee at the Josai University
Life Science Center performed in accordance with the “Standards
Relating to the Care and Management of Experimental Animals”
(Notice No. 6 of the Ofﬁce of the Prime Minister of Japan dated
March 27, 1980). Male KK mice at 6 weeks of age were obtained
from Tokyo Laboratory Animals Science Co. (Tokyo, Japan). All mice
were individually housed and allowed free access to water and feed
under the conditions of a 12-h light–dark cycle, a temperature of
22 ± 2 ◦C, and humidity of 55 ± 10% at Josai University Life Science
Center. Mice were fed a standard commercial rodent diet for 1 week
to stabilize metabolic conditions and divided into 6 groups (n = 5
in each group). All groups were fed experimental diets with con-
tents composed of 60% carbohydrates, 20% fats, and 20% protein
for 8 weeks. Dietary fats used safﬂower oil (Benibana Foods, Tokyo,
Japan) and/or ﬁsh oil (NOF, Tokyo, Japan). Safﬂower oil contained
78 wt%  oleic acid; ﬁsh oil contained 40.4 wt%  polyunsaturated fatty
acids, especially 6.6 wt%  EPA and 24.7 wt% DHA. SO diet contained
20% of calories from safﬂower oil, and FO diet contained 10% of calo-
ries from safﬂower oil and 10% from ﬁsh oil. SO and FO diets were
supplemented with 0.006% wt/wt (low-dose pioglitazone [PL]) or
0.012% wt/wt  (high-dose pioglitazone [PH]) pioglitazone and des-
ignated S/PL, S/PH, F/PL, or F/PH accordingly. Dietary details are
shown in Table 1. The feed were changed once in every 2–3 days,
and the residual amounts were recorded and showed as total food
intake during experimental periods. All diets were stored at −30 ◦C
until each meal is supplied freshly.
2.2. Computed tomography
Radiographic estimations of abdominal composition were per-
formed by computed tomography (CT) for experimental animals
using the mouse mode of the CT scanner (La Theta LCT100; ALOKA,
Tokyo, Japan). At the end of the experiment, mice fasted for 3 h
were anesthetized with intraperitoneal injections of pentobarbital
sodium (Dainippon Sumitomo Pharma, Osaka, Japan) before scan-
ning. Abdominal compositions of visceral and subcutaneous fats
were estimated by fat slice images at 2 mm intervals between the
second lumbar vertebra (L2) and L4 using La Theta software (ver-
sion 2.10).
2.3. Collection of blood and tissue samplesAfter CT scanning, blood samples were obtained from tail veins
of anesthetized mice. Glucose levels were measured using a blood
glucose monitoring system (One Touch Ultra; Johnson & Johnson,
Inc.). Mice were then immediately weighed prior to dissection.
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lood samples were obtained from the inferior vena cava and
reated with EDTA-2Na. Tissue samples, including liver, white adi-
ose tissue (WAT) around the epididymis, and brown adipose tissue
BAT), were immediately removed, weighed, frozen in liquid nitro-
en, and then stored at −80 ◦C until further use. Representative
mages of harvested whole livers from each group were taken using
 digital camera to assess macroscopic appearance. For histopatho-
ogical examination or morphometric analysis, samples of liver and
AT were collected from 4 to 5 mice per group, ﬁxed in 10% neu-
ral buffered formalin (Wako Pure Chemical Industries, Ltd., Osaka,
apan) and stained with hematoxylin and eosin (H&E, Kotobiken
edical Laboratoties, Inc., Tokyo, Japan). Blood samples were cen-
rifuged at 900 × g for 10 min  to collect plasma, which was  stored
t −80 ◦C until further use.
.4. Oral glucose tolerance tests
Oral glucose tolerance tests (OGTTs) were performed in 3 h
asted mice at 14 weeks of age. Glucose solutions were prepared
y diluting glucose in ultrapure water and orally administrated at
 dose of 1 g glucose/kg body weight. Blood samples were obtained
efore (0 min) and 30, 60, and 120 min  after glucose administra-
ion, and glucose levels were immediately measured using a blood
lucose monitoring system (One Touch Ultra; Johnson & Johnson,
nc.).
.5. Insulin tolerance tests
Insulin tolerance tests (ITTs) were performed in 3 h fasted mice
t 14 weeks of age by intraperitoneal injection of insulin (Humulin
; Lilly USA, Indianapolis, USA) diluted in saline at a dose of
.75 units/kg body weight. Blood glucose levels were determined
sing a similar protocol to OGTT. Blood glucose levels in response
o insulin were expressed as percentages of initial values prior to
nsulin administration.
.6. Measurement of hepatic lipid content and plasma
iochemical parameters
Hepatic lipid extraction was performed using approximately
00 mg  of liver tissue per mouse according to a previously described
ethod [36]. Hepatic triglyceride and total cholesterol levels,
nd plasma triglyceride, total cholesterol, high-density lipopro-
ein cholesterol (HDL-C), and FFA levels, were quantiﬁed by an
nzymatic colorimetric method using commercial kits (Wako E-
est kits; Wako Pure Chemical Industries Ltd., Osaka, Japan).
lasma insulin and leptin levels were determined by enzyme-
inked immunosorbent assay (ELISA) using Insulin ELISA kits and
eptin/mouse ELISA kits (Morinaga Institute of Biological Sci-
nce, Tokyo, Japan), respectively. Plasma adiponectin levels were
easured using Mouse/rat adiponectin ELISA kits (Otsuka Pharma-
eutical, Tokyo, Japan). Homeostasis model assessment of insulin
esistance (HOMA-IR) indices and plasma non-HDL-C levels were
alculated using the following formula: HOMA-IR, fasting blood
lucose (mg/dl) × fasting plasma insulin (U/ml)/405; plasma non-
DL-C, plasma total cholesterol (mg/dl) − plasma HDL-C (mg/dl).
.7. Liver and WAT  histopathology and adipocyte percentage
rea quantiﬁcation
H&E-stained liver and epididymal WAT  sections were examined
nder a microscope at 100-fold magniﬁcation. For morphometric
nalysis of epididymal WAT, adipocytes were manually traced and
uantitated with an image analysis system (ImageJ, Wayne Ras-
and, NIH). Four different ﬁelds per group were randomly capturedeports 3 (2016) 4–14
and white adipocyte areas were measured from more than 900 cells
per group.
2.8. RNA isolation and measurement of mRNA levels by real-time
polymerase chain reaction
TRIzol Reagent (Invitrogen Co.) was used to extract total RNA
from liver and WAT  samples from each mouse according to the
manufacturer’s protocol. Quantitative real-time polymerase chain
reaction (RT-PCR) was  performed using 1 g of total RNA per sam-
ple on an ABI Prism 7500 Sequence Detection System (Applied
Biosystems, Foster City, CA) using QuantiTect SYBR Green RT-PCR
kits (QIAGEN, Hilden, Germany) according to the manufacturer’s
instructions. Primer sequences used in the present study are shown
in Table 2. Thermal cycling conditions were set as follows: 1 cycle of
reverse transcription at 50 ◦C for 30 min, initial activation at 95 ◦C
for 15 min, then 40 cycles of denaturation at 94 ◦C for 15 s, annealing
at 55 ◦C for 30 s and extension at 72 ◦C for 1 min.
2.9. Statistical analysis
Values are presented as mean ± SD. Comparisons between
experimental groups were performed using one-way ANOVA fol-
lowed by the Tukey–Kramer test (Statview 5.0; SAS Institute Inc.,
USA). Means with different letters are different at P < 0.05.
3. Results
3.1. Combination of pioglitazone and ﬁsh oil suppresses weight
gain associated with subcutaneous fat accumulation in response
to pioglitazone in male KK mice
Greater body weight gain was  observed in the pioglitazone-
treated S/PL and S/PH groups compared with the non-treated SO
group; however, F/PL and F/PH groups had approximately 3 g less
body weight gain compared with the S/PL and S/PH groups, respec-
tively (Table 3). Epididymal WAT  weights in the S/PL, FO, F/PL, and
F/PH groups were signiﬁcantly lower than the SO group (Table 3).
There was a trend toward lower epididymal WAT  weights in
S/PH compared with the SO group. In pioglitazone-treated groups,
BAT weights were almost twice as great compared with non-
treated mice. No signiﬁcant difference in BAT weights was observed
between the SO and FO groups (Table 3). CT scanning analysis
revealed visceral fat mass weights were unchanged in response to
either pioglitazone or ﬁsh oil (Fig. 1A, B). However, subcutaneous
fat mass in the S/PL and S/PH groups was increased by 40% and 57%
compared with the SO group, respectively. The accumulation of
subcutaneous fat in the F/PL and F/PH groups was comparable with
the SO group, indicating amelioration of the effect of pioglitazone
by ﬁsh oil (Fig. 1A, C).
3.2. Combination of pioglitazone and ﬁsh oil improves glucose
metabolisms in male KK mice
To investigate the effects of the combination of pioglitazone and
ﬁsh oil on glucose metabolism, we  performed OGTT and ITT on
obese and diabetic male KK mice. In OGTT, no signiﬁcant differences
in blood glucose levels at 30, 60, or 120 min  were observed between
groups. No signiﬁcant differences in blood glucose area under the
curve (AUC) values were observed between groups (Fig. 2A). For ITT,
blood glucose levels at 30 min  after insulin injections were reduced
to approximately 80% and 60% of initial values in the F/PL and F/PH
groups, respectively, with differences maintained until 120 min. In
the F/PH group, blood glucose levels were signiﬁcantly lower at
120 min  after insulin injection than in the S/PH group (Fig. 2B).
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Table  2
Primers for real-time polymerase chain reaction.
Genes Forward(5′ → 3′) Reverse(3′ → 5′)
SREBP-1c GGAGCCATGGATTGCACATT GGCCCGGGAAGTCACTGT
Insig-1 TCACAGTGACTGAGCTTCAGCA TCATCTTCATCACACCCAGGAC
FAS TCACCACTGTGGGCTCTGCAGAGAAGCGAG TGTCATTGGCCTCCTCAAAAAGGGCGTCCA
SCD-1 CCGGAGACCCCTTAGATCGA TAGCCTGTAAAAGATTTCTGCAAACC
ACC TGACAGACTGATCGCAGAGAAAG TGGAGAGCCCCACACACA
GPAT TCATCCAGTATGGCATTCTCACA GCAAGGCCAGGACTGACATC
AOX TCAACAGCCCAACTGTGACTTCCATTA TCAGGTAGCCATTATCCATCTCTTCA
UCP-2 GTTCCTCTGTCTCGTCTTGC GGCCTTGAAACCAACCA
CPT-1 CCAGGCTACAGTGGGACATT GAACTTGCCCATGTCCTTGT
MCAD GAAGATCAAGCGAGGCTCCA CCTTCCTGCATTCCATCGTC
PEPCK GTGCTGGAGTGGATGTTCGG CTGGCTGATTCTCTGTTTCAGG
G6pase ACTGTGGGCATCAATCTCCTC CGGGACAGACAGACGTTCAGC
Adiponectin GCAGAGATGGCACTCCTGGA CCCTTCAGCTCCTGTCATTCC
TNF- TCTCATCAGTTCTATGGCCC GGGAGTAGACAAGGTACAAC
IL-6 TTCACAGAGGATACCACTCC GTTTGGTAGCATCCATCATT
MCP-1 GGCTCAGCCAGATGCAGT GAGCTTGGTGACAAAAACTACAG
GAPDH TGTGTCCGTCGTGGATCTGA CCTGCTTCACCACCTTCTTGAT
Table 3
Food intake, body weights, and tissue weights in 15-week-old male KK mice.
Group SO S/PL S/PH FO F/PL F/PH
Total food intake (g/mouse) 267 ± 33 270 ± 21 258 ± 20 277 ± 31 255 ± 7 242 ± 11
Initial  body weight (g) 29.8 ± 1.6 29.8 ± 1.6 29.8 ± 1.6 29.8 ± 1.5 29.8 ± 1.1 29.8 ± 1.1
Final  body weight (g) 42.3 ± 2.4 45.3 ± 4.1 45.9 ± 3.4 40.8 ± 2.3 42.3 ± 1.7 43.2 ± 1.7
Body  weight gain (g) +12.5 ± 1.3a,b +15.6 ± 2.7a +16.1 ± 2.6a +11.0 ± 3.1b +12.5 ± 2.1a,b +13.4 ± 1.5a,b
Liver weight (g) 2.54 ± 0.31b 3.85 ± 0.76a 2.95 ± 0.47a,b 2.18 ± 0.25b 2.77 ± 0.63b 2.20 ± 0.28b
WAT  weight (g) 1.52 ± 0.25a 1.14 ± 0.25b 1.21 ± 0.18a,b 1.11 ± 0.18b 0.94 ± 0.09b 1.02 ± 0.06b
BAT weight (g) 0.32 ± 0.04b 0.83 ± 0.13a 1.09 ± 0.32a 0.30 ± 0.06b 0.68 ± 0.16a,b 0.96 ± 0.34a
a Data are represented as mean ± SD (n = 5).
b Means with different letters are different at P < 0.05 by Tukey–Kramer test.
Fig. 1. X-ray computed tomography images, visceral fat, and subcutaneous fat in 15-week-old male KK mice. (A) CT images, (B) visceral fat mass, and (C) subcutaneous
f  safﬂo
l ks. Co
f  and fo
p
F
oat  mass. Representative CT scanned cross-sections from mice fed diets containing
ow-dose pioglitazone (S/PL, F/PL) or high-dose pioglitazone (S/PH, F/PH) for 8 wee
at  and subcutaneous fat were evaluated in abdominal regions between the secondPlasma insulin levels were signiﬁcantly decreased in all
ioglitazone-treated groups compared with the SO group. In the
O group, a trend toward decreased plasma insulin levels was
bserved compared with the SO group (Table 4). Similarly, HOMA-wer oil or ﬁsh oil diets without pioglitazone treatment (SO, FO) and treated with
lored regions represent visceral fat (pink) and subcutaneous fat (yellow). Visceral
urth lumbar vertebrae. Data are represented as mean ± SD (n = 4–5).IR indices were signiﬁcantly decreased in the S/PL, S/PH, F/PL, and
F/PH groups, with a trend toward a decrease in the FO group,
compared with the SO group (Table 4). No signiﬁcant differences
in plasma adiponectin levels were observed between the SO and
8 Y. Iizuka et al. / Toxicology Reports 3 (2016) 4–14
Fig. 2. Oral glucose tolerance tests (OGTTs) and insulin tolerance tests (ITTs) in 14-week-old male KK mice. (A) Blood glucose levels during OGTT and area under the
curve  values and (B) blood glucose levels during ITT. OGTT was performed by administration of a 10% glucose solution (1 g/kg) after 3 h of fasting. ITT was performed by
intraperitoneal injection of an insulin solution (0.75 U/kg) after 3 h of fasting. Blood samples were obtained immediately prior to glucose or insulin treatment (0 min) and at
30,  60, and 120 min  after glucose loading or insulin injection. Data are represented as mean ± SD (n = 5). The Tukey–Kramer test was used for statistical analyses. †, P < 0.05
for  comparison between S/PL and F/PH groups; ††, P < 0.05 for comparison between S/PH and F/PH groups.
Table 4
Blood glucose and metabolic parameters in 15-week-old male KK mice.
Group SO S/PL S/PH FO F/PL F/PH
Blood glucose (mg/dl) 287 ± 59 255 ± 52 347 ± 75 354 ± 120 290 ± 66 288 ± 31
Plasma  insulin (ng/ml) 50.2 ± 25.3a 19.8 ± 7.2b 6.2 ± 3.9b 31.4 ± 17.1a,b 16.9 ± 8.8b 9.8 ± 4.6b
HOMA-IR 1.00 ± 0.45a 0.36 ± 0.13b,c 0.15 ± 0.09c 0.68 ± 0.35a,b 0.36 ± 0.22b,c 0.20 ± 0.10b,c
Plasma adiponectin (g/ml) 10.3 ± 0.8c 19.6 ± 2.9b,c 30.9 ± 8.8b 12.7 ± 2.3c 28.9 ± 5.4b 68.2 ± 12.9a
Plasma leptin (ng/ml) 68.3 ± 14.7 64.7 ± 10.1 67.8 ± 9.9 57.9 ± 9.5 63.1 ± 8.1 67.7 ± 19.3
Plasma  TG (mg/dl) 193 ± 52a 146 ± 29a,c 168 ± 25a,b 187 ± 24a 116 ± 23b,c 93 ± 23c
Plasma TC (mg/dl) 176 ± 21a 167 ± 15a 163 ± 15a 115 ± 11b 86 ± 9c 76 ± 5c
Plasma HDL-C (mg/dl) 135 ± 18a 131 ± 13a 123 ± 12a 82 ± 10b 73 ± 10b 61 ± 6b
Plasma non HDL-C (mg/dl) 41 ± 7a 36 ± 8a 41 ± 9a 33 ± 3a 14 ± 5b 15 ± 2b
Plasma FFA (mEq/l) 0.74 ± 0.12a 0.56 ± 0.12a,b 0.50 ± 0.09b 0.48 ± 0.08b 0.41 ± 0.10b,c 0.28 ± 0.05c
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pData are represented as mean ± SD (n = 5).
b HOMA-IR are shown as ratio to SO group.
c Means with different letters are different at P < 0.05 by Tukey–Kramer test.
O groups. However, plasma adiponectin levels were higher in
ioglitazone-treated groups compared with non-treated groups,
ith signiﬁcant differences observed in some groups. In particu-
ar, the F/PH group had a 2.2-fold signiﬁcant increase in plasma
diponectin levels compared with the S/PH group (Table 4).
Hepatic expression levels of genes related to gluconeogen-
sis are shown in Fig. 6. Phosphoenolpyruvate carboxykinase
PEPCK) mRNA levels were signiﬁcantly decreased in the S/PL and
/PH groups compared with the SO group, whereas no changes
ere observed in ﬁsh oil-fed groups. No signiﬁcant differences
n glucose-6-phosphatase (G6pase) mRNA levels were observed
etween all groups.
.3. Combination of pioglitazone and ﬁsh oil improves plasma
ipid proﬁles in male KK mice
To examine the effects of the combination of pioglitazone and
sh oil on plasma lipid proﬁles, plasma lipid levels were measured,
ith the results shown in Table 4. No signiﬁcant differences in
riglyceride levels were observed among the SO, S/PL, S/PH, and
O groups. Triglyceride levels were signiﬁcantly lower in the F/PL
nd F/PH groups compared with the SO group. No signiﬁcant dif-
erences in total plasma cholesterol levels were observed between
ioglitazone-treated and untreated safﬂower oil-fed groups. Totalplasma cholesterol levels were signiﬁcantly decreased in ﬁsh
oil-fed groups treated with pioglitazone (F/PL and F/PH) com-
pared with the FO group. HDL-cholesterol levels were signiﬁcantly
decreased in ﬁsh oil-fed groups compared with safﬂower oil-fed
groups, regardless of pioglitazone treatment (Table 4). Plasma FFA
levels were signiﬁcantly decreased in all groups, except the S/PL
group, compared with the SO group. Plasma FFA levels in the F/PH
group were signiﬁcantly lower than in the S/PH group.
3.4. Pioglitazone treatment induces accumulation of liver
triglyceride, but ﬁsh oil feeding suppresses that in male KK mice
To examine the effects of the combination of pioglitazone and
ﬁsh oil on hepatic lipid accumulation, we  performed histological
analysis on liver specimens and measured hepatic lipid contents.
Liver tissues had the palest appearance, characteristic of severe
steatosis, in the S/PL group (Fig. 3A). A greater severity steato-
sis was observed in liver sections from the S/PL and S/PH groups
than the SO group, with minimal steatosis observed in the FO
group (Fig. 3B). Similarly, liver triglyceride levels were signiﬁcantly
increased in pioglitazone-treated S/PL (2.2-fold) and S/PH (1.6-fold)
groups compared with those in the SO group. Liver triglyceride lev-
els in the FO group were signiﬁcantly decreased compared with
those in the SO group. Increased liver triglyceride levels in response
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Fig. 3. Liver morphology, histological sections, and liver lipid parameters in 15-week-old male KK mice. (A) Liver morphology, (B) liver histology, (C) liver triglyceride
levels,  and (D) liver total cholesterol levels. Representative macroscopic liver images and tissue sections from mice fed safﬂower oil or ﬁsh oil diets without pioglitazone
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o pioglitazone were signiﬁcantly reduced to the level of the SO
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lthough liver total cholesterol levels were signiﬁcantly increased
n the S/PL group than the SO group, liver total cholesterol levels
n ﬁsh oil-fed groups (FO, F/PL, and F/PH) were signiﬁcantly lower
han in the SO group (Fig. 3D).
.5. Combination of pioglitazone and ﬁsh oil ameliorates
dipocyte hypertrophy and increases the number of small
dipocytes in male KK mice
To clarify the interaction between the amelioration of insulin
esistance in response to pioglitazone and ﬁsh oil treatment and
hanges in visceral fat parameters, we performed histological
nalysis on WAT  sections (Fig. 4A). Mean adipocyte areas were
igniﬁcantly lower in the S/PH, F/PL, and F/PH groups compared
ith groups not treated with pioglitazone. No difference in mean
dipocyte areas was observed between the FO group and SO group.
ean adipocyte areas were signiﬁcantly lower in the F/PH group
ompared with the S/PH group (Fig. 4B). Evaluation of adipocyte
ize distributions demonstrated lower peak sizes in the F/PL
nd F/PH groups (2500–3600 m2) compared with other groups.
he percentages of small adipocytes (400–3600 m2) and larger
dipocytes (>6400 m2) were increased and decreased, respec-
ively, in the F/PL and F/PH groups compared with other groups
Fig. 4C).tazone (S/PH, F/PH) for 8 weeks. Sections were stained by H&E and examined under
s with different letters are different at P < 0.05 by Tukey–Kramer test.
3.6. Fish oil feeding decreases hepatic mRNA levels of genes
involved in lipogenesis with or without pioglitazone treatment
To elucidate the mechanisms underlying the amelioration of
weight gain and subcutaneous fat accumulation in response to
pioglitazone by the combination of pioglitazone and ﬁsh oil, we
measured hepatic mRNA expression of genes involved in de novo
lipogenesis (Fig. 5). SREBP-1c mRNA levels were signiﬁcantly
decreased in all pioglitazone-treated groups compared with the
SO group, with no difference observed between the SO and FO
groups. Insulin-induced gene 1 (Insig-1) mRNA levels were sig-
niﬁcantly decreased in ﬁsh oil-fed groups. Insig-1 mRNA levels in
the F/PL and F/PH groups were approximately 60% lower than in
the S/PL and S/PH groups, respectively. Expression levels of SREBP-
1c target genes, such as FAS, SCD-1, and ACC, were signiﬁcantly
decreased in ﬁsh oil-fed groups, regardless of pioglitazone treat-
ment (Fig. 5). In addition, mRNA levels of glycerol-3-phosphate
acyltransferase (GPAT), a lipogenic rate-controlling enzyme, were
increased in the S/PL and S/PH groups compared with the SO group;
however, increased expression of GPAT was  markedly suppressed
by the combination of pioglitazone with ﬁsh oil (Fig. 5).
3.7. Pioglitazone, but not ﬁsh oil, increases hepatic mRNA levels of
genes involved in ˇ-oxidationTo elucidate the association between -oxidation and suppres-
sion of fat accumulation by the combination of pioglitazone and
ﬁsh oil, we  measured hepatic mRNA expression of genes involved
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Fig. 4. WAT  histological sections, mean adipocyte areas, and cell size distributions in 15-week-old male KK mice. (A) Epididymal WAT  sections stained with H&E, (B) mean
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n fatty acid -oxidation and metabolism. AOX mRNA levels were
igniﬁcantly increased in the S/PL, S/PH, and F/PH groups compared
ith the SO group. No difference in AOX mRNA levels was observed
etween the SO and FO groups (Fig. 6). Although pioglitazone and
sh oil did not signiﬁcantly affect UCP-2 mRNA expression, there
as a trend toward increased levels of UCP-2 mRNA levels in the
/PL and S/PH groups compared with the SO group (Fig. 6). Carnitine
almitoyltransferase 1 (CPT-1) and medium-chain acyl-CoA dehy-
rogenase (MCAD) mRNA levels were unaffected by pioglitazone
r ﬁsh oil (Fig. 6).
.8. Pioglitazone and ﬁsh oil decreases cytokine mRNA expression
n WAT
To elucidate the relationship between histological changes and
hronic inﬂammation in response to the combination of pioglita-
one and ﬁsh oil, cytokine mRNA expression levels were measured
n epididymal fat. No signiﬁcant differences in adiponectin mRNA
evels were observed between groups; however, there was  a trend
oward increased adiponectin expression in the S/PH and F/PH
roups compared with the SO group. TNF- mRNA levels were
ower in pioglitazone-treated groups compared with the SO group,
ith signiﬁcant differences observed in some groups. No signiﬁcant
ifference in TNF- mRNA levels was observed in response to ﬁshfrom mice fed safﬂower oil or ﬁsh oil diets without pioglitazone treatment (SO, FO)
) for 8 weeks. Sections were stained by H&E and examined under a microscope at
letters are different at P < 0.05 by Tukey–Kramer test.
oil. Interleukin 6 (IL-6) mRNA levels were signiﬁcantly decreased
in the S/PL, FO, F/PL, and F/PH groups and tended to attenuate in
the S/PH group compared with the SO group. MCP-1 mRNA lev-
els were signiﬁcantly lower in pioglitazone and/or ﬁsh oil treated
groups compared with the SO group (Fig. 7).
4. Discussion
Pioglitazone is widely used as an insulin sensitizer in the
treatment of type 2 diabetes. However, body weight gain accom-
panied by an increase in subcutaneous fat is frequently observed
in patients treated with pioglitazone and is considered a major
adverse effect of pioglitazone. To address this substantial clinical
issue, we examined the utility of ﬁsh oil consumption in ameliorat-
ing pioglitazone-induced body weight gain and further elucidated
the beneﬁcial effects of the combination of pioglitazone and ﬁsh oil
on glucose and lipid metabolism.
In the present study, we  found that the combination of pioglita-
zone and ﬁsh oil ameliorated body weight gain and subcutaneous
fat accumulation in response to pioglitazone treatment. In addi-
tion, pioglitazone and/or ﬁsh oil-treated mice had signiﬁcantly
lower epididymal fat weight. However, no signiﬁcant differences
in visceral fat mass were observed between the treatment groups.
Majority of FFAs released from the triglycerides of chylomicron and
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Fig. 5. Hepatic mRNA levels related to lipogenesis in 15-week-old male KK mice. Mice were fed safﬂower oil or ﬁsh oil diets without pioglitazone treatment (SO, FO) and
treated with low-dose pioglitazone (S/PL, F/PL) or high-dose pioglitazone (S/PH, F/PH) for 8 weeks. Panels show mRNA levels of SREBP-1c, Insig-1, FAS, SCD-1, ACC and
GPAT. mRNA levels were determined by real-time quantitative PCR. Results are expressed as the ratio of the obtained value to that of the Safﬂower oil (SO) group. Data are
represented as mean ± SD (n = 5). Groups with different letters are different at P < 0.05 by Tukey–Kramer test.
Fig. 6. Hepatic mRNA levels related to fatty acid -oxidation and metabolism, and gluconeogenesis in 15-week-old male KK mice. Mice were fed safﬂower oil or ﬁsh oil diets
w PL, F/P
A al-tim
o ith di
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f
tithout pioglitazone treatment (SO, FO) and treated with low-dose pioglitazone (S/
OX,  UCP-2, CPT-1, MCAD, PEPCK, and G6pase. mRNA levels were determined by re
f  the Safﬂower oil (SO) group. Data are represented as mean ± SD (n = 5). Groups wLDL particles are re-esteriﬁed to triacylglycerol in adipose tissue
or storage [37]. Thus, ﬁsh oil consumption is thought to decrease
riacylglycerol supply to adipose tissue by reducing VLDL produc-L) or high-dose pioglitazone (S/PH, F/PH) for 8 weeks. Panels show mRNA levels of
e quantitative PCR. Results are expressed as the ratio of the obtained value to that
fferent letters are different at P < 0.05 by Tukey–Kramer test.tion, thereby inhibiting the accumulation of lipids in adipose tissue
[33,35]. Our results demonstrate ﬁsh oil consumption potently
decreases mRNA expression of lipogenic enzymes, including FAS,
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Fig. 7. Cytokine mRNA levels in epididymal fat of 15-week-old male KK mice. Mice were fed safﬂower oil or ﬁsh oil diets without pioglitazone treatment (SO, FO) and treated
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CD-1, ACC, GPAT, and SREBP-1c. The majority of lipogenic gene
xpression levels were unchanged or increased in S/PL and S/PH
roups despite decreased expression of SREBP-1c mRNA. These
esults are coincident with previous study used KKAy mice by Oribe
t al. [38]. On the other hands, it has reported that pioglitazone
nhibits nuclear translocation of SREBP-1c and represses lipogenic
ene expression in lean C57BL6/J mice [39]. These data showed
hat lipogenic gene expressions in response to pioglitazone vary
onsiderably depending on obesity or non-obesity.
Expression levels of fatty acid -oxidation related genes, includ-
ng AOX, UCP-2, CPT-1, and MCAD, were unaffected by ﬁsh oil
onsumption. These results suggest diets with 10% of total calo-
ies provided by ﬁsh oil had no effect on -oxidation in the present
tudy. Our previous studies demonstrated diets with 2% of total
alories provided by ﬁsh oil signiﬁcantly increased AOX and UCP-2
RNA levels in C57BL/6 mice [40]; however, diets with 2–25% of
otal calories provided by ﬁsh oil were not found to stimulate -
xidation in obesity-induced KK mice fed a high fat diet [41]. These
eports suggested ﬁsh oil-induced effects on stimulating fatty acid
-oxidation may  be attenuated by obesity in female KK mice. In the
resent study used male KK mice, also, diets with 10% of total calo-
ies provided by ﬁsh oil were found to potently inhibit lipogenesis
ithout activation of fatty acid -oxidation, resulting in decreased
ccumulation of subcutaneous fat and body weight gain in response
o pioglitazone treatment.
TZDs have been reported to ameliorate IR by increasing plasma
diponectin levels in obese and diabetes murine models and clin-
cal trials [12,42–44]. Our data demonstrated plasma adiponectin
evels were increased in pioglitazone-treated groups with signiﬁ-
antly decreased HOMA-IR indices compared with correspondingks. Panels show mRNA levels of adiponectin, TNF-, IL-6, and MCP-1. mRNA levels
e obtained value to that of the Safﬂower oil (SO) group. Data are represented as
 test.
pioglitazone-untreated groups. On the other hand, ﬁsh oil treat-
ment alone was  found to have no marked effect on these
parameters. Fish oil supplementation reportedly increases circu-
lating adiponectin levels in non-obese rodents [45,46]. However,
our previous study demonstrated diets with 2.5%, 12.5%, and 25%
of total calories provided by ﬁsh oil had no beneﬁcial effects on
plasma adiponectin and insulin levels in KK mice [41]. These ﬁnd-
ings suggest the antidiabetic effects of ﬁsh oil related to circulating
adiponectin levels may be attenuated by obesity. In the present
study, adiponectin levels in the F/PH group were 2.2-fold higher
than in the S/PH group despite few notable effects on other parame-
ters observed. Increased plasma adiponectin levels may  contribute
to the amelioration of IR in male KK mice; however, adiponectin
levels above a certain level may  not necessarily correspond to an
insulin sensitizing effect.
The KK mouse model has signiﬁcantly greater severity of hyper-
insulinemia and IR compared with wild-type mice, with maximum
dysfunction observed at 16–20 months of age [47]. In the present
study, treatment of male KK mice with pioglitazone led to signiﬁ-
cantly decreased plasma insulin levels and improved IR compared
with pioglitazone-untreated groups. However, these changes may
be insufﬁcient to greatly decrease blood glucose levels in OGTT.
Pro-inﬂammatory cytokines produced by adipose tissue
macrophages (ATMs) in adipose tissue are closely associated with
obesity and IR [48]. ATMs can be classiﬁed into two phenotypes:
the pro-inﬂammatory M1  phenotype and the anti-inﬂammatory
M2 phenotype. M1 ATMs are seen to accumulate in obese adipose
tissue and secrete pro-inﬂammatory cytokines including TNF-,
IL-6, and MCP-1. M1  ATMs have been shown to promote adi-
pose tissue lipolysis via activation of mitogen-activated protein
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inases resulting in increased FFA production, particularly satu-
ated fatty acids. In addition, the FFAs have been shown to act as
 ligand for toll-like receptor-4 (TLR-4) expressed by macrophages
nd cause further exacerbation of chronic inﬂammation in adipose
issue [49]. Dietary n-3 polyunsaturated fatty acids, such as EPA
nd DHA, inhibited TLR-induced inﬂammatory signaling pathways
50]. And, pioglitazone treatment increased the ratio of M2-to-M1
TMs in epididymal fat of diet-induced obese mice, and changes
n the number of ATMs were closely correlated with IR [51]. In
his study, ﬁsh oil consumption or/and pioglitazone treatment
ecreased expression of pro-inﬂammatory cytokines, such as TNF-
, IL-6, and MCP-1, in epididymal fat. Our results suggest that ﬁsh
il and/or pioglitazone ameliorated inﬂammation in adipose tissue
nd improved IR.
Hepatic lipid accumulation is closely related to IR and com-
ensatory hyperinsulinemia. TZDs have been reported to potently
timulate the differentiation of adipocytes and induce a redis-
ribution of FFAs from extra-adipose tissues, including the liver
nd pancreas, to newly derived adipocytes, thereby ameliorating
hole-body IR and fatty liver [6,18]. In contrast, several studies
ave demonstrated the anti-steatotic effect of TZDs in both ani-
als and humans [19,39,52]. Bedoucha et al. reported markedly
ncreased hepatic levels of PPAR mRNA and protein in diabetic
KAy and ob/ob mice compared with lean C57BL6/J mice [53]. Fur-
her, prominent microvesicular steatosis due to lipid accumulation
as observed in KKAy mice treated with TZDs, suggesting obese
ice are more susceptible to TZD-induced steatosis than lean mice.
n the present study, pioglitazone monotherapy induced dramatic
epatic triglyceride accumulation in male KK mice, particularly
n the S/PL group, in addition to stimulating expression of genes
elated to fatty acid synthesis. And, pioglitazone-induced hepatic
ipogenesis was potently inhibited by ﬁsh oil consumption, con-
ributing to the efﬁcacy of the combination of TZD and ﬁsh oil in
he treatment of type 2 diabetes.
. Conclusions
In conclusion, we demonstrated that the combination of piogli-
azone and ﬁsh oil may  prevent the adverse effects of pioglitazone
reatment on promoting excessive body weight gain and subcuta-
eous fat accumulation. Fish oil consumption was found to potently
nhibit hepatic lipogenesis in KK mice. The results of this study
uggest that the combination of pioglitazone and ﬁsh oil has partic-
lar efﬁcacy in diabetic patients with fatty liver and adipose tissue
nﬂammation. Thus, we provide novel data regarding the utility of
utritional therapy in patients with type 2 diabetes being treated
ith pioglitazone.
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